Voyager Therapeutics/VYGR

$8.24

-2.25%
-
1D1W1MYTD1YMAX

About Voyager Therapeutics

Voyager Therapeutics, Inc. is a biotechnology company focused on advancing neurogenetic medicines. The Company’s pipeline includes programs for Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Parkinson’s disease, and multiple other diseases of the central nervous system. Many of its programs are derived from its TRACER AAV capsid discovery platform, which is used to generate novel capsids and identify associated receptors to potentially enable high brain penetration with genetic medicines following intravenous dosing. Its pipeline of programs, all of which are in preclinical development, include Anti-Tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy Program, Tau Silencing Gene Therapy Program, Vectorized Anti-Amyloid Antibody Early Research Program, Friedreich’s Ataxia Program: VY-FXN01, GBA1 Gene Replacement Program, HD Program, and others. VY-TAU01 is for the treatment of Alzheimer’s disease. SOD1 Silencing Gene Therapy Program is for the treatment of ALS.

Ticker

VYGR

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Alfred Sandrock

Employees

162

Headquarters

Lexington, United States

VYGR Metrics

BasicAdvanced
$457.75M
Market cap
2.85
P/E ratio
$2.96
EPS
0.96
Beta
-
Dividend rate
$457.75M
0.96085
$14.34
$6.06
630.8K
4.956
1.699
51.83%
89.61%
70.85%
2.849
1.831
1.571
1.937
6.131
511.16%
344.59%
13.47%
44.52%

What the Analysts think about VYGR

Analyst Ratings

Majority rating from 10 analysts.
Buy

Price Targets

Average projection from 9 analysts.
115.78% upside
High $30.00
Low $10.00
$8.24
Current price
$17.78
Average price target

VYGR Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
62.55% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$90M
1,856.52%
Net income
$56.3M
-317.37%
Profit margin
62.55%
-111.11%

VYGR Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 533.17%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$2.94
-$0.51
-$0.59
$1.25
-
Expected
$0.77
-$0.57
-$0.58
-$0.29
-$0.44
Surprise
280.99%
-10.3%
1.5%
-533.17%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Voyager Therapeutics stock?

Voyager Therapeutics (VYGR) has a market cap of $457.75M as of April 16, 2024.

What is the P/E ratio for Voyager Therapeutics stock?

The price to earnings (P/E) ratio for Voyager Therapeutics (VYGR) stock is 2.85 as of April 16, 2024.

Does Voyager Therapeutics stock pay dividends?

No, Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders as of April 16, 2024.

When is the next Voyager Therapeutics dividend payment date?

Voyager Therapeutics (VYGR) stock does not pay dividends to its shareholders.

What is the beta indicator for Voyager Therapeutics?

Voyager Therapeutics (VYGR) has a beta rating of 0.96. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Voyager Therapeutics stock price target?

The target price for Voyager Therapeutics (VYGR) stock is $17.78, which is 115.78% above the current price of $8.24. This is an average based on projections from 9 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Voyager Therapeutics stock

Buy or sell Voyager Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing